We have previously shown that emodin suppresses tyrosine kinase activity of HER-2/neu-encoded p185 neu receptor tyrosine kinase. In this study, we examine the relationship between the chemical structure and the activity of emodin and nine derivatives, and identi®ed that one methyl, one hydroxy, and one carbonyl functional groups are critical for the biological activities of emodin. We also found that one of the derivatives 10-(4-acetamidobenzylidene)-9-anthrone (DK-V-47) is more eective than emodin in repressing the tyrosine phosphorylation of p185 neu and in inhibiting the proliferation and transformation of HER-2/neu-overexpressing human breast cancer cells. Using mutation-activated HER-2/neu transformed 3T3 cells, we also investigated whether emodin and DK-V-47 can inhibit malignant transformation induced solely by the HER-2/neu oncogene. We found that DK-V-47 is more potent than emodin in suppressing transformation phenotypes of activated HER-2/neu transformed 3T3 cells including anchoragedependent and -independent growth, metastasis-associated properties. These results clearly indicate that the inhibition of p185 neu tyrosine kinase by both emodin and DK-V-47 is capable of suppressing the HER-2/neu associated transformed phenotypes including the ability to induce metastatic potential. Our results also support the chemotherapeutic implications of the use of either emodin or DK-V-47 to target HER-2/neu-overexpressing cancer cells.
Introduction
The HER-2/neu gene (also known as c-erbB-2) encodes a 185 neu transmembrane tyrosine kinase (p185 neu ) homologous to epidermal growth factor receptor (EGFR) Coussens et al., 1985; Bargmann et al., 1986; Semba et al., 1985; Yamamoto et al., 1986) . Ampli®cation and/or overexpression of HER-2/neu has been detected frequently in many human cancers (Slamon et al., 1987 (Slamon et al., , 1989 Zhang et al., 1989; Schneider et al., 1989; Weiner et al., 1990; Yokota et al., 1988; Zhau et al., 1990; Hou et al., 1992; Myers et al., 1994) . Its enhanced expression is correlated with chemotherapeutic drug resistance in some experimental systems Tsai et al., 1993 Tsai et al., , 1995 , number of lymph node metastases in node positive breast cancer patients (Slamon et al., 1987; Lacroix et al., 1989; Tauchi et al., 1989) and shortened survival in breast, ovarian, lung, oral and gastric cancer patients (Sadasivan et al., 1993; Veltri et al., 1994; McCann et al., 1991; Vijver et al., 1987; Gusterson et al., 1992; Toikkanen et al., 1992; Berchuck et al., 1990; Xia et al., 1997; Yoshida et al., 1989) . Cellular and animal experiments have shown that an increase in HER-2/neu expression enhances malignant phenotypes of cancer cells, including metastatic potential (Yu and Hung, 1991; Yu and Hung, 1991; Yu et al., 1994; Yusa et al., 1990) . The association of HER-2/neu overexpression in cancer cells with chemoresistance and metastasis provides a plausible interpretation for the poor clinical outcome of patients with HER-2/neu-overexpressing cancers; it suggests that enhanced tyrosine kinase activity of HER-2/neu plays a critical role in the initiation, progression, and outcome of human tumors.
Emodin (3 methyl-1,6,8 trihydroxyanthraquinone) is an inhibitor of protein tyrosine kinase (Jayasuriya et al., 1992) which was isolated from Polygonum Cuspidatum. Emodin was recently shown to suppress HER-2/neu tyrosine kinase activity in HER-2/neuoverexpressing human breast and lung cancer cells (Zhang et al., 1995; Zhang and Hung, 1996) . It has also been shown to sensitize HER-2/neu-overexpressing lung cancer cells to chemotherapeutic drugs (Zhang and Hung, 1996) .
In an attempt to search for compounds more eective than emodin to inhibit HER-2/neu tyrosine kinase activity and cell transformation, we examined the relationship between the chemical structure and activity of the derivatives of emodin on tyrosine phosphorylation of HER-2/neu. We found that one of nine of the derivatives, 10-(4-acetamidobenzylidene)-9-anthrone (DK-V-47) is more eective than emodin in repressing tyrosine phosphorylation of p185 neu , in inhibiting growth, and in suppressing the transformation phenotypes of these cancer cells. Because it is not clear whether emodin and DK-V-47 might also exhibit other biological activity which could also contribute to the suppression of the malignance of human cancer cells, it is critical to determine whether the two compounds can inhibit malignant transformation induced solely by the HER-2/neu oncogene. To address this issue, we included HER-2/neu transformed 3T3 cells in our study.
Results
Eect of emodin and its derivatives on HER-2/neuoverexpressing human breast cancer MDA-MB 453 cells To determine the relationship between chemical structures of emodin and its derivatives and their inhibitory activities on the tyrosine phosphorylation of HER-2/neu and on the proliferation of HER-2/neuoverexpressing breast cancer cells, we synthesized nine derivatives as shown in Figure 1 . We separated the derivatives of emodin into four groups, according to substitute at the dierent structural position of emodin. We treated human breast cancer MDA-MB 453 cells that overexpress p185
neu with varying concentrations of ten compounds at 378C for 24 h in the absence of serum. We then analysed the ten compounds to determine the protein level of p185 neu and its tyrosine phosphorylation, we used immunoblotting with antiphosphotyrosine antibody for the detection of phosphotyrosine (anti-PY) and anti-p185 neu antibody for the detection of p185 neu . As summarized in the Table 1 , of the ten compounds tested the carbon 10 (C 10 ) group substitute DK-V-47 was revealed to be the most eective in suppressing the tyrosine phosphorylation of p185 neu ; the parent compound emodin is slightly less eective. To achieve a 50% inhibitory activity of tyrosine phosphorylation, 21 mM of emodin and 17 mM of DK-V-47 are required. Emodin and its nine derivatives under the same condition did not aect the protein levels of p185 neu (data not shown). We also investigated the eects of emodin and its derivatives on the proliferation of MDA-MB 453 cells. Cells were treated with dierent concentrations of the compounds at 378C for 72 h and then measured by the MTT assay. As also shown in Table 1 , DK-V-47 is the most eective compound inhibiting cell growth; the IC 50 of emodin is ®vefold higher than that of DK-V-47.
The ®ndings from four groups also indicate that the methyl group at C 3 , the hydroxy group at C 6 and the carbonyl group at C 10 position are critical for maintaining the activity of emodin required to suppress the tyrosine phosphorylation of HER-2/neu and to block the growth of HER-2/neu-overexpressing breast cancer cells. However, when the ketone at C 10 is replaced by the p-acetamidobenzylidene group, the compound DK-V-47 demonstrates more potent activity than does emodin. The CH 3 CO group in the backbone of DK-V-47 appear to be critical for the biological activity; replacement of this group by H almost completely abolishes the biological activities.
We have previously shown that, among the dierent biological assays, suppression by emodin is much more profound in the soft agarose colonization assay; this assay which is used to measure the ability of cells to grow in an anchorage-independent environment, represents transformation status of cells in vitro. As shown in Figure 2 , when DK-V-47 was examined for its eect on breast cancer cells in a soft agarose Cells were treated by dierent concentrations of emodin and derivatives for 72 h in the presence of serum, then proliferation of cells were measured by MTT assay as described in Materials and methods Emodin inhibits HER-2/neu-induced transformation and metastasis L Zhang et al colonization assay, the colony formation activity of both breast cancer cells MDA-MB-453 and MCF-7 were suppressed in a dose-dependent manner. However, at the same concentrations of the drug (either at 0.5 or at 2.0 mM) the HER-2/neu overexpressing MDA-MD-453 cells (Figure 2a ) are much more sensitive to the drugs than the MCF-7 cells (Figure 2b ) which express basal levels of p185 neu (at 0.5 mM, P50.001; at 2.0 mM, P50.001).
In addition, as shown in Figure 2 , the activity of DK-V-47 to suppress anchorage-independent growth is much more potent than that of emodin (P50.0001), for example, at a concentration of 0.5 mM, DK-V-47 shows signi®cant inhibitory activity for the HER-2/neuoverexpressing MDA-MB-453 cells in colony formation, to achieve similar inhibition, higher than 20 mM emodin is required. The profound eect of the dierential suppression of DK-V-47 and emodin on MDA-MB-453 cells in the soft agarose colonization assay compared with other biological assays such as the tyrosine phosphorylation of p185 neu and the cell proliferation by MTT assay, as shown in Table 1 , could be due to the fact that the dierent incubation times of the compounds with cells are required for dierent assays; 2 ± 3 weeks are needed for the soft agarose colonization assay, whereas only 2 ± 3 days are needed for other assays.
Emodin and DK-V-47 induce G 0 /G 1 arrest Since cell cycle distribution is closely related to cell proliferation rate, both eective compounds, emodin and DK-V-47 were further subjected to cell cycle distribution analysis (Figure 3 ). The number of cells in S-phase is apparently reduced and those in G 0 /G 1 phase signi®cantly increased. The results indicated that both compounds are able to inhibit DNA replication and to induce cell cycle arrest at G 0 /G 1 phase, suggesting that cell cycle arrest may contribute to the growth inhibition.
Cell growth inhibition by emodin is reversible
In order to determine if inhibition of emodin on cell growth is stable or transitory, we treated MDA-MB-453 cells with 40 mM emodin for 3 days in the presence of serum, and washed o the reagents. These cells were then incubated with fresh serum-containing medium along with or without emodin for dierent time intervals. The viable cells was then measured by MTT assay and the fraction of viable cells was calculated by de®ning the absorption of cells without treatment of emodin as 100%. As shown in Figure 4 , after cells were treated with 40 mM of emodin for 3 days, the fraction of viable cells decreased to 38% compared with untreated cells. For the cells continuously treated with emodin for the additional 5 days, the cell growth remained inhibited. However, when emodin was washed out after 3-day treatment, the cells started to grow and the growth rate was similar to the untreated cells in the subsequent time course. These results indicate that inhibitory eect by emodin is reversible.
Repression of autophosphorylation and transphosphorylation by emodin and DK-V-47 in vitro
While the results just described suggest that tyrosine kinase inhibitors such as emodin and DK-V-47 preferentially suppress the transformation phenotype of HER-2/neu-overexpressing MDA-MB-453 human cancer cells, it should be noted that these human cancer cells are derived from dierent patients and are likely associated with multiple genetic alterations. HER-2/neu expression may not be the only genetic dierence between these two cancer cell lines.
To speci®cally investigate the eects of the tyrosine kinase inhibitors on HER-2/neu mediated transformation phenotypes, we would need transformed cells of which the transformation phenotypes are induced solely by HER-2/neu oncogene. To achieve this, we used an NIH3T3 transfectant, B104-1-1, which was transformed by the transfection of the mutationactivated rat HER-2/neu oncogene (Hung et al., 1989; Emodin inhibits HER-2/neu-induced transformation and metastasis L Zhang et al Bargmann et al., 1986; Bargmann and Weinberg, 1988) . The mutation-activated p185 neu in B104-1-1 is known to be associated with high tyrosine kinase activity. The transformation phenotypes associated with B104-1-1 cells are induced solely by the HER-2/ neu oncogene. Therefore, the B104-1-1 cells served as an excellent model system to study the eects of emodin and DK-V-47 on the transformation phenotype induced by HER-2/neu oncogene. In addition, the phenotype induced by expression of mutated p185 neu has been reported to be similar to overexpression of normal p185
neu that also results in overall increase of tyrosine kinase activity. Therefore, the mutated p185 neu has been used as a model to understand overexpression of normal p185
neu . To address whether emodin and DK-V-47 can directly inhibit the tyrosine kinase activity of activated HER-2/neu, p185 neu was immunoprecipitated from the untreated B104-1-1 cells. The precipitates were then treated with varying concentrations of emodin and DK-V-47, and the kinase activity was measured, as shown in Figure 5 , the tyrosine kinase activity for both autophosphorylation for p185 neu and transphosphorylation for enolase is inhibited by both emodin and DK-V-47 in a dose-dependent manner. DK-V-47 is more potent than emodin, a ®nding which is consistent with tyrosine phosphorylation status of p185 neu in breast cancer cells shown in Table 1 . These results further demonstrate that both emodin and DK-V-47 directly inhibit the tyrosine kinase activity of p185 neu complex.
DK-V-47 is more potent than emodin in inhibiting both anchorage-dependent and -independent growth of B104-1-1 cells
Next, we examined the eects of the two tyrosine kinase inhibitors on cell growth rate. As shown in Figure 6a , the growth of HER-2/neu transformed 3T3 cells, B104-1-1 cells was inhibited by both emodin and DK-V-47 to varying degrees in a dose-dependent manner. At 80 mM concentration, for example, emodin and DK-V-47 blocked 55% and 83% of the growth of B104-1-1 cells respectively. However, under the same condition, both emodin and DK-V-47 had little eect on the parental 3T3 cells. These results indicate that emodin and DK-V-47 preferentially suppress growth of HER-2/neu transformed cells, and that DK-V-47 is more potent than emodin. They also suggest that the dierential suppression eect occurs through the inhibition of the p185 neu tyrosine kinase activity, because the tyrosine kinase inhibitors have virtually no eect on the parental 3T3 cells. When the anchorage-independent growth activity of B104-1-1 cells was measured by a soft agarose colonization assay as shown in Figure 6b , Figure 4 Cell growth inhibition by emodin is reversible. MDA-MB 453 cells were treated with or without 40 mM emodin in the presence of serum for 3 days, and then washed o the reagents. After that, the cells were incubated with fresh medium either in the presence or absence of emodin for dierent times, the viable cells were measured by MTT assay, and fraction of viable cells was calculated by de®ning the absorption of cells without treatment of emodin as 100%. All determinations were made in triplicate Emodin and DK-V-47 suppress metastasis-associated properties induced by HER-2/neu oncogene Tumor metastasis is a complex process involving a sequential series of critical steps (Liotta, 1986; Nicolson, 1988 Nicolson, , 1991 . The impartation of tumor cells in microcirculation and the subsequent invasion of blood vessel basement membrane are very important steps during blood-born metastasis. Gelatinase, type IV collagenases, has been shown to play a critical role in the dissolution of the basement membrane collagen during tumor cell invasion and metastasis (Nicolson, 1989) . We have previously demonstrated that HER-2/ neu transformed 3T3 cells can induce experimental metastasis in nude mice and enhance gelatinase activities (Yu and Hung, 1991) . To determine whether or not emodin and DK-V-47 can decrease the activity of gelatinase collagenase IV in B104-1-1 cells, we examined the gelatinase activity in B104-1-1 cells with zymographic analysis. As shown in Figure 7 , both DK-V-47 (A) and emodin (B) inhibit gelatinolytic activity of the 92 kDa and 68 kDa gelatinase, and this inhibition is enhanced with higher concentrations of both compounds. These results demonstrate that DK-V-47 is more eective than emodin; for example, at a concentration of 10 mM, DK-V-47 shows signi®cant inhibitory activity for gelatinase, to achieve similar suppression, 40 mM of emodin is required. Cancer cell invasion is very important; to be metastatic, malignant cells in the blood must extravasate from the circulation, invade basement membrane and colonize distant sites. Activated HER-2/neu transformed 3T3 cells have been shown to be invasive (Yu and Hung, 1991) . To determine whether or not emodin and DK-V-47 can abolish the invasive properties of activated HER-2/neu transformed cells, we performed in vitro invasion assay to monitor their eects. As shown in the Figure 8 , both compounds can virtually abolish the ability of activated HER-2/neu transformed cells to penetrate the Matrigel layer. For repressing the invasive ability of HER-2/neu transformed cells, DK-V-47 is again more eective than emodin (P50.0001 at 25 mM and P50.05 at 50 mM).
Using the NIH3T3 cells transformed by the mutation-activated HER-2/neu oncogene, B104-1-1, as a model system, the results shown in Figures 5 ± 8 clearly demonstrate that both emodin and DK-V-47 can inhibit the tyrosine kinase activity of p185 neu and thus abolish the transforming phenotypes induced by the HER-2/neu oncogene. These results support the conclusion that repression of p185 neu tyrosine kinase by these two compounds is probably the major mechanism which induces the preferential suppression of Reactants were resolved on 7.5% SDS ± PAGE. The phosphorylation products were dried and visualized by autoradiography, as described in Materials and methods Emodin inhibits HER-2/neu-induced transformation and metastasis L Zhang et al biological activities for HER-2/neu-overexpressing cancer cells. The results also indicate that DK-V-47 is a much stronger suppressor than is emodin for HER-2/ neu-induced transformation phenotypes.
Discussion
In our previous study (Zhang et al., 1995) , we demonstrated that emodin suppresses the tyrosine kinase activity of HER-2/neu and preferentially inhibits cell growth and the transformation phenotype in vitro for human breast cancer cells that overexpress the HER-2/neu oncogene. Furthermore, we found that emodin can sensitize HER-2/neu overexpressing non-small-cell lung cancer (NSCLC) cells to chemotherapeutic drugs such as cisplatin, doxorubicin and VP16, to which these cells are resistant (Zhang and Hung, 1996) .
In the present study, we examined the relationship between the chemical structure and the inhibitory activity of emodin and its nine derivatives on the tyrosine phosphorylation of p185 neu and on the proliferation of human breast cancer cells. We identi®ed that one of the nine derivatives, DK-V-47, is more eective than emodin in repressing the tyrosine phosphorylation of p185 neu and in suppressing the transformation phenotype induced by the HER-2/neu oncogene. We have also found that emodin and DK-V-47 may arrest cell growth at G 0 /G 1 phase by increasing numbers of cells in G 0 /G 1 phase and reducing the numbers of cells in S-phase, under the same condition, we did not observe any apoptosis induced by treatment of either emodin or DK-V-47 (data not shown).
In our previous studies, we used human breast and lung cancer cells with dierent levels of HER-2/neu expression. It is well known that human cancer cell lines are associated with multiple genetic alterations, and HER-2/neu expression is not the only dierence among the various human cancer cell lines. To investigate the speci®c eects of the tyrosine kinase inhibitors on the tyrosine kinase of p185 neu , in the present study, we used a HER-2/neu-transformed NIH3T3 cells line, B104-1-1, as a model. The results clearly indicate that DK-V-47 is a more potent suppressor than emodin in repressing the tyrosine kinase activity of p185 neu ( Figure 5 ) and, accordingly, in transformation phenotypes induced by the HER-2/ neu oncogene. In addition to dierential activity to repress tyrosine kinase of p185 neu , we could not rule out the possibility that membrane permeability might also contribute to the dierent potencies between emodin and DK-V-47. Taken together, this study provides strong evidence that repression of the p185 neu tyrosine kinase activity by emodin and DK-V-47 plays a major With regard to the relationship between the structure of emodin and its nine derivatives and their inhibitory activity, the ten compounds were studied in four functional groups as shown in Table 1 and Figure 1 . The ®rst group is comprised of the compounds in which the CH 3 group at the C 3 position of emodin is replaced by one of four other functional groups. Their activities for the inhibition of the tyrosine phosphorylation of p185 neu and the proliferation of cells are dramatically reduced; suggesting that the CH 3 group at the C 3 position is critical for these activities. The OH group at C 6 position of emodin is replaced by either H or OCH 3 group in the second group. These modi®cations also diminish the inhibitory activity as compared with emodin; this ®nding indicates that the OH group at the C 6 position is also critical for inhibitory activity. In the third group, the ketone group at C 10 position of emodin is replaced by H group. Its inhibitory activities were signi®cantly decreased as compared with emodin. These results indicate that the carbonyl group at C 10 position is important for maintaining the inhibitory activity of emodin. The fourth group is comprised of the compounds in which the ketone at C 10 position of emodin is replaced by the p-acetamidobenzylidene group. The compound DK-V-47 demonstrates more potent activity than does emodin. The CH 3 CO group in the backbone of DK-V-47 appear to be critical for the biological activity; replacement of this group by H almost completely abolishes the biological activities. The hydroxyl group at C 6 , methyl group at C 3 and the ketone group at C 10 are important for the biological activity of emodin as shown in Table 1 . Interestingly, DK-V-47 which does not have C 6 hydroxyl and C 3 methyl groups is also associated with profound potency. The data suggest that multiple functional groups may contribute to the biological activities of emodin backbone, and a more systematic study is required to address the detailed structural and functional relationship. Scholar and Toews (1994) reported that the tyrosine kinase inhibitor genistein can inhibit the invasion of murine mammary carcinoma cells; repression of tyrosine phosphorylation may be the mechanism. We have previously shown that both the mutation-activated HER-2/neu oncogene and overexpression of the normal HER-2/neu gene can enhance critical metastatic potential including the invasive ability to penetrate the basement membrane preparation Matrigel (Yu and Hung, 1991; Yu et al., 1994) . Both mutation-activation and the overexpression of HER-2/neu result in increased tyrosine kinase activity. And as shown in Figures 5, 7 and 8, we have shown that both emodin and DK-V-47 can inhibit the tyrosine kinase activity of mutationactivated HER-2/neu in 3T3 cells, and both compounds can repress the secretion of gelatinase and invasive potential. These ®ndings suggest that tyrosine kinase activity of HER-2/neu is required for the metastatic process, and that inhibitors of the tyrosine kinase activity of HER-2/neu such as emodin and DK-V-47 can repress metastasis induced by activated HER-2/neu.
In our preliminary study, we found that emodin can also repress EGF-induced tyrosine phosphorylation of EGF receptor at higher concentration, compared with the concentration which used to repress tyrosine phosphorylation of HER-2/neu (data not shown). It would be interesting to further study whether emodin or DK-V-47 might have dierential selectivity in repression of activities of dierent tyrosine kinase molecules.
In summary, our results indicate that a tyrosine kinase inhibitor such as emodin or DK-V-47 which is capable of repressing the tyrosine kinase activity of HER-2/neu can eectively inhibit the transformation, and in vitro invasion of HER-2/neu overexpressing cancer cells. The stronger tyrosine kinase inhibitor DK-V-47 may serve as a better suppressor of HER-2/neumediated transformation than emodin. These results may have important chemotherapeutic implications. Emodin and DK-V-47 inhibit in vitro invasion of activated HER-2/neu-transformed 3T3 cells. In vitro invasion was measured by using 24-well Transwell units with an 8 mm pore polycarbonate ®lter coated with Matrigel to form a thin, continuous layer on the ®lter top. The lower compartment contained 0.6 ml of laminin (20 mg/ml) as a chemo-attractant. Activated HER-2/neu-transformed cells (5610 4 ) were placed in the upper compartment and treated or not treated for three days with emodin or DK-V-47 in the presence of serum. The lower surfaces of the ®lters from the Transwell units were then ®xed with 3% glutaraldehyde in PBS and stained with Giemsa solution (a). Chemo-invasive activity was determined under the microscope by counting cells that had migrated to the lower side of the ®lter (b). All experiments were done in triplicate; the results are means+s.d.
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Materials and methods
Preparation of emodin derivatives
All emodin derivatives were prepared from emodin using the synthetic procedures described previously (Kim et al., in press ). These compounds are stable under the cell culture condition, no decomposition was observed within 72 h at 378C.
Cell culture
Human breast cancer cells MDA-MB453, overexpressing HER-2/neu and MCF-7 cells expressing basal level of HER-2/neu were obtained from the American Type Culture Collection (Rockville, MD). The activated HER-2/neu transformed 3T3 cell line, B104-1-1, was established by transfecting the rat point mutation neu which possess high tyrosine kinase activity, into NIH3T3 cells Stern et al., 1986; Bargmann and Weinberg, 1988) . All cells were grown in DMEM/F12 (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum and gentamicin (50 mg/ml). Cells were grown in a humidi®ed incubator at 378C under 5% CO 2 in the air.
Western blot analysis
Cells were treated by dierent concentrations of emodin and derivatives for 24 h in the absence of serum, then cells were washed three times with PBS and lysed in lysis buer (20 mM Na 2 PO 4 , pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% aprotinin, 1 mM phenylmethysulfonyl¯uoride, 10 mg/ ml leupeptin, 100 mM NaF, 2 mM Na 3 VO 4 ) as previously described (Zhang et al., 1995) . The protein content was determined against a standardized control using the BioRad protein assay kit (Bio Rad Laboratories, Hercules, CA). A total of 50 mg of protein was separated by 6% SDS ± PAGE and transferred to nitrocellulose ®lter paper (Schleicher & Schuell, Inc., Keene, NH). Nonspeci®c binding on the nitrocellulose ®lter paper was minimized with a blocking buer containing non-fat dry milk (5%) and Tween 20 (0.1%, v/v) in PBS (PBS/Tween 20). The treated ®lter paper was incubated with primary antibodies (anti-p185neu antibody c-neu for the detection of p185 neu or with anti-phosphotyrosine antibody [UBI, Lake Placid, NY] for the detection of phosphotyrosine). This was followed by incubation with HRP-goat-anti-mouse antibody (1 : 1000 dilution) (Boehringer Mannheim Corp., Indianapolis, IN). Bands were then visualized with an enhanced chemiluminescense system (Amersham Corp., Arangton, IL) and quantitated using`NIH Image' software.
Immuno-complex kinase assay
The immuno-complex kinase assay was modi®ed from those described previously (Zhang et al., 1995) . Brie¯y, untreated cells were collected and then lysed in lysis buer. Cell lysates (500 mg) were incubated with monoclonal antip185 neu antibody c-neu (Ab-3) for 1 h at 48C, then precipitated with 50 ml of protein-A-conjugated agarose (Boehringer Mannheim) for 30 min at 48C. The cells were then washed three times with 50 mM Tris-HCl buer containing 0.5 M LiCl (pH 7.5) and once in an assay buer (50 mM Tris-HCl, pH 7.5, 10 mM MnC12). To 40 ml of beads (protein-a-conjugated agarose), 10 mCi of [g-32 P]ATP (Amersham) and 10 ml of enolase (Sigma Chemical Co., St. Louis, MO) and 1.0 ml of dierent concentrations of emodin and DK-V-47 were added and incubated at room temperature for 20 min. The reactants were separated by 7.5% SDS ± PAGE. The gel was then dried, visualized by autoradiography and quantitated bỳ NIH Image' software.
Cell proliferation by MTT assay
Cells were detached by trypsinization, seeded at 2610 4 cells/ ml in a 96-well microtiter plate overnight, and then treated with dierent concentrations of test samples of emodin and its derivatives and incubated for an additional 72 h in the presence of serum. The eects on cell growth were examined by MTT assay (Mosmann et al., 1983; Rubinstein et al., 1990) . Brie¯y, 20 ml of MTT solution (5 mg/ml) (Sigma) was added to each well and incubated at 378C for 4 h. The supernatant was aspirated, and the MTT formazan formed by metabolically viable cells was dissolved in 150 ml of DMSO, and then monitored by a microplate reader (Dynatech MR 5000¯uorescence, Dynatech Corp., Burlington, MA) at a wavelength of 590 nM.
DNA content analysis
MDA-MB453 cells were treated with or without either emodin (40 mM) or DK-V-47 (20 mM) for 3 days in the presence of serum, then cells were collected by trypsinization and ®xed for 30 min at 7208C in 70% ethanol, 30% phosphate buered saline (PBS) mixture. After staining with PBS containing 50 mg/ml propidium iodide and 8 mg/ ml RNase A, cells were analysed on EPICS PROFILE¯ow cytometer (Coulter) as described .
Colony formation in soft agarose
Cells were seeded in 24-well plates (1610 3 cells/well) in culture medium containing 0.35% agarose (FMC Corp., Rockland, ME) over a 0.7% agarose layer and incubated for 4 weeks at 378C, as previously described (Zhang et al., 1995) . Colonies were then stained with p-iodonitrotetrazolium violet (1 mg/ml), and colonies larger than 100 mM were counted. Each measurement was made four times.
Zymography of gelatinolytic activity
As previously described (Yu and Hung, 1991; Yu et al., 1994) , cells were detached by trypsinization, seeded at 2610 6 cells/well in a 6-well plate and cultured in DMEM/ F12 medium supplemented with 1% FBS overnight, the cells were then washed with PBS and serum-free DMEM/ F12 medium was added; then the cells were treated with dierent concentrations of test samples and incubated for an additional 24 h. The culture supernatants were collected, and then centrifuged at 800 g for 10 min, and then again at 18 000 g for 10 min. The supernatants (150 ml) were analysed by zymography using SDS ± PAGE containing 1.5% gelatin prepared according to procedures described previously (Yu and Hung, 1991; Yu et al., 1994) .
In vitro chemoinvasion assay
In vitro invasiveness was conducted according to the procedure described previously (Yu and Hung, 1991; Yu et al., 1994) , with modi®cations. Brie¯y, 24-well Transwell units with 8-mm pore size polycarbonate ®lter (Costar Corp., Cambridge, MA) were coated with 0.1 ml of a 1 : 30 dilution (48 mg/®lter) of Matrigel in cold DMEM/F12 medium. These ®lters were then air dried at room temperature, thus forming a continuous thin layer on top of the ®lter. The lower compartment contained 0.6 ml laminin (20 mg/ml, Becton Dickinson) as a chemoattractant or DMEM/F12 medium as a negative control. The cells (1610 5 cells/0.1 ml of DMEM/F12 containing 0.1% bovine serum albumin) were placed in the upper compartment and incubated with or without either emodin or DK-V-47 at 378C for 72 h in a humidi®ed atmosphere of 95% air, and 5% CO 2 . Following incubation, the ®lters were ®xed with 3% glutaraldehyde in PBS and stained with Giemsa. The number of cells per high-power (6200) ®eld Emodin inhibits HER-2/neu-induced transformation and metastasis L Zhang et al that had migrated to the lower side of the ®lter were counted.
Statistical analysis
Statistical analysis was performed with student's t test.
Abbreviations
Abbreviations used are: DK-V-47, 10-(4-acetamidobenzylidene)-9-anthrone; DMEM/F12, Dulbecco's modi®ed Eagle's medium/Ham's F-12; PBS, phosphate-buered saline; SDS ± PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis; MTT, [3] [4] 
